News
In a research published in the PLOS Journal, the scientists in China have revealed about some never-before-seen viruses in the bats that live close to humans. These viruses are quite closely related ...
A group of experts investigating Covid origins on behalf of the World Health Organization revealed they still aren't sure how ...
Trump’s new COVID-19 website features five arguments supporting the lab. Among them was the explanation that Wuhan – the Chinese city where the virus first began spreading – is home to a ...
A LEADING theory that the Covid pandemic originated from a lab leak in China cannot be ruled out, the World Health ...
The number of COVID-19 cases is increasing in parts of the U.S. and worldwide amid the emergency of a sub-variant known as "razor blade throat COVID." The variant — NB.1.8.1. or “Nimbus” – got the ...
The New Coronavirus Variant Surging in China Has Arrived in The Us. Here’s What to Know About Nimbus
A new coronavirus variant is spreading in many parts of the world. The variant, NB.1.8.1, has been identified as the cause of Covid-19 resurgence in China and several other Asian countries. Experts in ...
The new coronavirus variant surging in China has arrived in the US. Here’s what to know about Nimbus
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information and tools designed to improve your well-being. A new coronavirus variant is ...
The COVID-19 variant that may be driving a recent rise in cases in some parts of the world has earned a new nickname: “razor blade throat” COVID. That’s because the variant — NB.1.8.1. or ...
Mayoral candidate and former governor Andrew Cuomo refused to apologize for his COVID-19 nursing home policy when faced with a grieving son at the NYC Democratic mayoral debate. Matthew McDermott ...
The Wyss Institute for Biologically Inspired Engineering, where researchers developed a compound that could become a new coronavirus treatment, is located in Boston. By Julian J. Giordano ...
German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results